There is more evidence from the San Diego biotech scene that
investment is flocking back to RNAi Therapeutics, from all sorts of sources. Following successful public offerings by the
likes of Arrowhead Research and Alnylam and multi-million dollar VC rounds in
two smaller RNAi Therapeutics companies earlier this year, the investment this
time is coming from a large diversified company and private investors.
Nitto Denko Tackles Fibrosis
With the initiation of clinical development for an RNAi Therapeutics in fibrosis, not Merck, not Novartis or Takeda, but Japanese materials manufacturer Nitto Denko has
become the largest company yet to enter an RNAi Therapeutics into the clinic which originated from internal R&D. The newest
addition to the RNAi Therapeutics pipeline is based on research from Prof.
Niitsu’s laboratory at Sapporo Medical University and involves a vitamin
A-targeted liposome for gene knockdown of a collagen-specific chaperone (Hsp47)
in fibrogenic cells. Subsequent to the
seminal Nature Biotech publication on gene knockdown in hepatic stellate cells
for not just the stabilization, but even the reversal of liver fibrosis (Sato et al. 2008), a more recent publication applying the same formulation in pancreatic fibrosis
indicates that Nitto Denko is considering ND-L02-s0201 for fibroses beyond the
liver.
Of note, the RNAi trigger design came
from Quark Pharmaceuticals (Tuschl workarounds with lots of non-canonical
modifications) and Nitto Denko itself has become the world’s largest clinical supplier
of oligonucleotides following its 2011 acquisition of Avecia.
Fibrosis is becoming a hot area in Oligonucleotide
Therapeutics with a number of companies (RXi Pharmaceuticals, Excaliard/Pfizer,
Sirnaomics, BMT etc) chasing fibroses in the skin, eye, liver, and beyond. As fibrosis is a complication, often the most debilitating consequence of many diseases involving inflammation
(think fatal diseases such as idiopathic pulmonary fibrosis), and little
progress has been made in reversing it, the expanded target space available to
oligonucleotide therapeutics could bring unique opportunities at changing the
way we think about the disease.
RNAi Start-up Arcturus Therapeutics Raises $1.3M in
Private Investor Round
Coincidental with the Nitto Denko trial initiation, San
Diego-based Arcturus Therapeutics announced that it has raised $1.3M in a
private investor round. Arcturus
Therapeutics, curiously founded by former Nitto Denko employees, is said to be
developing a liver-targeted RNAi Therapeutics for an unnamed rare/orphan disease
indication. It appears that the value of Arcturus is based on a nanoparticle delivery technology. Although the nature of the formulation is yet
to be disclosed, my impression is that it is a liposomal one given the
background of the company founders and the liver indication.
It is very good seeing examples like that where the RNAi
Therapeutics appetite is reaching down to the grass-roots levels, unfathomable even
just 1 ½ years ago. While I once worried
that the RNAi Therapeutics dry spell (2008-2011) could prove disastrous to
innovation in the industry, some seeds were able to survive. I look forward to following the progress of
these technologies and companies as they grow.
